Literature DB >> 6259978

Lymphocyte responses to virus and mitogen in ponies during experimental infection with equine herpesvirus 1.

S K Dutta, A Myrup, M K Bumgardner.   

Abstract

Six pony foals, experimentally infected with equine herpesvirus 1 (EHV-1), were studied for their lymphocyte responses to EHV-1 and phytohemagglutinin (PHA) stimulations. Lymphocyte blastic transformation in the presence of EHV-1 appeared as early as 2 days after the foals were inoculated, reached a peak in 7 to 10 days, and subsequently decreased. In contrast, the lymphocyte blastic transformation in the presence of PHA increased sharply, reaching a peak in 2 to 3 days, and then decreased to its lowest level in 10 days after which it returned to its near preinoculation level. As for the mechanism of the transient hyporesponsiveness to mitogen, sera from the ponies after inoculation did not cause lessened stimulatory response of normal lymphocytes to PHA. The possible mechanism of this transient hyporesponsiveness to mitogen is discussed.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6259978

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  4 in total

1.  Genetic restriction of cytolysis during equid herpesvirus 1 subtype 2 infection.

Authors:  C G Bridges; N Edington
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

2.  Transforming growth factor-beta induced by live or ultraviolet-inactivated equid herpes virus type-1 mediates immunosuppression in the horse.

Authors:  S Charan; K Palmer; P Chester; A R Mire-Sluis; A Meager; N Edington
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

3.  Infectious center assay of intracellular virus and infective virus titer for equine mononuclear cells infected in vivo and in vitro with equine herpesviruses.

Authors:  S K Dutta; A C Myrup
Journal:  Can J Comp Med       Date:  1983-01

4.  Innate immunity during Equid herpesvirus 1 (EHV-1) infection.

Authors:  C G Bridges; N Edington
Journal:  Clin Exp Immunol       Date:  1986-07       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.